The Ministry of Health of the Russian Federation has registered the medicine “Carbetocin, solution for intravenous and intramuscular injection 100 μg/ml” manufactured by FSUE “Endopharm”.
Marketing autorization No. LP-007763.
The medicine “Carbetocin, solution for intravenous and intramuscular injection” (INN carbetocin) belongs to the oxytocin pharmacotherapeutic group and its analogues and is used to prevent postpartum hemorrhage caused by uterine atony.
Carbetocin is a long-acting oxytocin agonist, which determines its pharmacological properties. Like oxytocin, carbetocin selectively binds to oxytocin receptors in the uterine smooth muscle, stimulates rhythmic uterine contractions, increases the frequency of existing contractions, and forces up uterine muscle tone. After the delivery, carbetocin is able to increase the frequency and strength of spontaneous uterine contractions. After intramuscular or intravenous injection of carbetocin (within 2 minutes after injection), the uterine muscles begin to rapidly and steadily contract. A single injection of carbetocin at a dose of 100 μg is sufficient to maintain adequate uterine contractions preventing uterine atony and profuse hemorrhage, which can be compared with intravenous infusion of oxytocin for several hours.
FSUE “Endopharm” plans to release the first commercial batches of the medicine in the second quarter of 2022.
Comment type is not specified in the component properties.